Eastman Kodak Donates Patents to McLean Hospital for Development of ADHD Screening Test
FOR IMMEDIATE RELEASE:
May 17, 2003
Belmont, MA - McLean Hospital announced today its receipt of a family of patents donated by the Eastman Kodak Company for the development of new diagnostic technology for attention deficit hyperactivity disorder (ADHD).
Kodak's System Concepts Center developed several innovations, collectively referred to as the ADHD Rapid Check technology, which have the potential to lead to a new process for the objective screening of ADHD, one of the most commonly diagnosed-and misdiagnosed-psychiatric disorders in children.
Medical professionals and families of patients who suffer from ADHD consider current testing procedures for ADHD complex and highly subjective, and have long sought a more cost-effective, physiologically based screening tool.
Kodak researchers developed the technology in 2001 while examining the therapeutic effect of images. To better understand how images could be used to reduce stress levels, adult subjects were deprived of visual and auditory stimuli for 10 minutes, during which time their stress levels were monitored by measuring the temperature of their fingers. In analyzing this data, the team discovered several subjects' temperature measurements were very different from the other subjects. Upon further analysis, the research team discovered a definite statistical significance among ADHD subjects and the remainder of the subjects tested. After further testing was conducted on school-aged children by Kodak and third parties, it was determined that the technology could be useful in testing for ADHD.
Martin Teicher MD, PhD, a world-renowned physician and a leading researcher known for developing and commercializing objective testing for physiological and psychological disorders, will head the research at McLean Hospital.
"Kodak is a recognized leader in the science and technology of images. The time and effort the Kodak research team applied to the ADHD Rapid Check technology may accelerate our ability to diagnose and treat ADHD," said Teicher, director of McLean Hospital's Development Biopsychiatry Research Program. "These inventions could help lay the foundation for improving the speed and accuracy of ADHD tests, which would be a tremendous comfort to families impacted by ADHD."
James Stoffel, MD, chief technology officer and director of Research and Development for Eastman Kodak, said: "In our pursuit of info-imaging, we often discover technologies outside Kodak's core businesses. The ADHD Rapid Check technology is a great example how our research sometimes leads in unexpected directions. While Kodak focuses on technological innovation in the consumer and commercial imaging markets, the researchers at McLean Hospital are ideally suited to move this important technology forward and determine the best path to successfully apply the inventions to ADHD testing, In future years, this donation may have a positive impact on patients and families affected by ADHD."
Once at McLean Hospital, the ADHD Rapid Check technology will require further research and testing before it can reach its full market potential. In addition to the technology, Kodak has also donated a grant to McLean to facilitate additional research. As recipient of the technology, McLean Hospital will benefit from all future worldwide revenues if ADHD Rapid Check is successfully commercialized.
Kodak worked with donology LLC, a company that specializes in the process of technology donations, to ensure that a thorough and objective process was used in valuing the ADHD Rapid Check technology and selecting the best organization to lead the research and commercialization efforts of the donated assets.